通过生物标志物识别高危患者并实施KDIGO指南预防心脏手术后急性肾损伤:PrevAKI随机对照试验
该单中心随机对照试验旨在评估对心脏手术高危患者实施KDIGO指南集束化治疗(优化容量与血流动力学、避免肾毒性药物、预防高血糖)能否预防心脏手术后急性肾损伤(AKI)。高危定义为尿[TIMP-2]·[IGFBP7]>0.3。主要终点为术后72小时内KDIGO标准定义的AKI发生率。结果显示干预组AKI发生率显著低于对照组(55.1% vs 71.7%,ARR 16.6%,95%CI 5.5-27.9%,P=0.004),中重度AKI发生率也显著降低;干预组不同时间点血流动力学参数显著改善、高血糖更少、ACEi/ARBs使用更少。其他次要结局无显著影响。作者结论认为实施KDIGO指南较标准治疗降低了高危患者心脏手术后AKI的频率和严重程度,需要足够把握度的多中心试验来检验死亡率和长期肾脏结局。
要点
- 高危定义为尿[TIMP-2]·[IGFBP7]>0.3的心脏手术患者,实施KDIGO集束化治疗使术后72小时内AKI发生率从71.7%降至55.1%(ARR 16.6%,95%CI 5.5-27.9%,P=0.004)。
- 干预组中重度AKI发生率也显著低于对照组。
- 集束化治疗包括优化容量状态和血流动力学、避免肾毒性药物、预防高血糖。
- 干预组不同时间点血流动力学参数显著改善(P<0.05),高血糖更少(P<0.001),ACEi/ARBs使用更少(P<0.001)。
- 其他次要结局(包括透析需求、住院时间、第30/60/90天MAKE)无显著影响。
适用人群与场景
- 接受心脏手术且尿[TIMP-2]·[IGFBP7]>0.3的高危患者。
诊断标准与关键阈值
- 高危定义:尿[TIMP-2]·[IGFBP7]>0.3。
- AKI诊断标准:KDIGO标准,评估术后72小时内AKI发生率。
处置流程与药物剂量
- KDIGO集束化治疗包括优化容量状态和血流动力学、避免肾毒性药物、预防高血糖。
研究设计与关键结果
- 单中心随机对照试验,纳入接受心脏手术且尿[TIMP-2]·[IGFBP7]>0.3的高危患者,干预为KDIGO集束化治疗,对照为标准治疗。
- 主要终点:术后72小时内KDIGO标准定义的AKI发生率干预组55.1% vs 对照组71.7%,ARR 16.6%(95%CI 5.5-27.9%),P=0.004。
- 中重度AKI发生率干预组较对照组显著降低。
- 干预组不同时间点血流动力学参数显著改善(P<0.05),高血糖更少(P<0.001),ACEi/ARBs使用更少(P<0.001)。
- 其他次要结局(透析需求、住院时间、第30/60/90天MAKE)无显著影响。
证据类型、等级与局限
- 证据类型:单中心随机对照试验。
- 局限:作者结论指出需要足够把握度的多中心试验来检验死亡率和长期肾脏结局。
对床旁实践的改变
- 对接受心脏手术且尿[TIMP-2]·[IGFBP7]>0.3的高危患者,实施KDIGO集束化治疗(优化容量状态和血流动力学、避免肾毒性药物、预防高血糖)可降低术后72小时内AKI发生率和中重度AKI发生率。
- 该干预对透析需求、住院时间及第30/60/90天MAKE无显著影响。
- 作者认为需要足够把握度的多中心试验来检验死亡率和长期肾脏结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Care bundles are recommended in patients at high risk for acute kidney injury (AKI), although they have not been proven to improve outcomes. We sought to establish the efficacy of an implementation of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines to prevent cardiac surgery-associated AKI in high risk patients defined by renal biomarkers.
METHODS: In this single-center trial, we examined the effect of a "KDIGO bundle" consisting of optimization of volume status and hemodynamics, avoidance of nephrotoxic drugs, and preventing hyperglycemia in high risk patients defined as urinary [TIMP-2]·[IGFBP7] > 0.3 undergoing cardiac surgery. The primary endpoint was the rate of AKI defined by KDIGO criteria within the first 72 h after surgery. Secondary endpoints included AKI severity, need for dialysis, length of stay, and major adverse kidney events (MAKE) at days 30, 60, and 90.
RESULTS: AKI was significantly reduced with the intervention compared to controls [55.1 vs. 71.7%; ARR 16.6% (95 CI 5.5-27.9%); p = 0.004]. The implementation of the bundle resulted in significantly improved hemodynamic parameters at different time points (p < 0.05), less hyperglycemia (p < 0.001) and use of ACEi/ARBs (p < 0.001) compared to controls. Rates of moderate to severe AKI were also significantly reduced by the intervention compared to controls. There were no significant effects on other secondary outcomes.
CONCLUSION: An implementation of the KDIGO guidelines compared with standard care reduced the frequency and severity of AKI after cardiac surgery in high risk patients. Adequately powered multicenter trials are warranted to examine mortality and long-term renal outcomes.
参考来源
- Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017. PMID: 28110412. doi:10.1007/s00134-016-4670-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。